Recombinant human MCP-1 tumor cells in bone planting the role of prevention MCP-1 protein expression were significantly increased, thereby improving yields. The reduced GST dissociation can be collected with high purity MCP-1, and does not affect the chemotaxis, activation of the biological characteristics of monocytes. 32MCP inhibition of osteosarcoma cells grown in 1. In this experiment, B, ~ E, osteosarcoma cells inoculated at the same time the sub-application of different doses of MCP-1, the CE group results suggest that MCP-1 significantly prevented the planting of osteosarcoma cells, application of a very small dose (ig,) MCP-1 A1 The group also significantly delayed the growth of osteosarcoma cells, a month after planting the tumor inhibition index was 69.69%, which proves that the MCP-1 inhibition of osteosarcoma cells grown significantly effect. Due to the high degree of malignancy of osteosarcoma, the tumor cells can easily stay in other parts of the body and form metastases. To deal with the tumor cells applied to clinical tumor resection within the surgical field contamination, planting, MCP-1 has an extremely important anti-tumor significance for early Fuzhou General Hospital of September 2003 10 3 osteosarcoma and chemotherapy patients residual cancer cells after treatment. A tumor cell growth inhibition 3.3MCP principle. Vivo and in vitro studies have shown that: most of the tumor-associated macrophages (TAM) are derived from the peripheral blood mononuclear cells, macrophages infiltrating the tumor site, which can produce many regulatory factors, enzymes, oxidation of metabolites and play phagocytosis , thus affecting tumor growth. The cells formed tumors the size of the tumor and its tumor the number of macrophages was negatively correlated (r = 0.81, P <0.001). Single gold / macrophage regulation by the organism, chemokine B family. In the common family of six members (MCPs a 1, 2 of MCP, the MCP-3 and MIP-la, RANTES), the MIP, a 1p. MCP-1 is the most effective, the most potent monocyte chemoattractant protein [cited. Tumors produced by MCP-1 is considered to be an important reason for the TAM gathered. The experiment proved to produce infiltration and its apparent increase in the total number of macrophages within the tumor in the tumor cells at a high level of MCP ~ l, and the low index of tumor inoculation, tumor invasion speed is relatively slow [4J. Topical application of MCP-1 may become a cancer therapeutic approach. This experiment suggested that MCP-1 did not improve the body’s peripheral blood mononuclear cells in the total number, but can play targets in lesion orientation focus on the role of anti-tumor. 3.4 Given the high degree of malignancy of osteosarcoma cells, the simple application of MCP-1 drug treatment flesh aneurysm clinical effect can be considered with chemotherapy drugs and other collaborative applications [cited. Especially in the clinical treatment of certain difficult to completely remove the lesion, such as the spine, spinal cord and other parts of the tumor, surgery, topical application may obtain better results. MCP-1 has a different mechanism for tumor therapy and other methods, application compatibility, improve immunity, improve anti-tumor effects of the drug and reduce its toxic side effects. Partial use of MCP-1 can be raised mononuclear cells to improve immunity to kill residual tumor in the body tissue cells, reduce the recurrence of osteosarcoma index. 3.5MCP an adverse reaction on the body. Monocytes / macrophages cytotoxic to malignant tumors, while normal cells are relatively weak, and even are not toxic. Secretion of MCP-1 tumor cells in the host (mice) did not show the tumor cells demonstrated the secretion of TNF toxicity and cachexia. The Luster such as MCP-1 is missing like LPS, TNF, IL-1, IL-2, IL-4 produced by systemic toxicity, thus showing a high dose tolerance. Inflammatory cells, the role of the chemokine MCP-1 play in the process of inflammation, the development of many diseases, lesions and MCP-1. In addition, MCP-1 can be caused by infiltration of mononuclear cells express high levels of MCP-1 body did not show infiltration of mononuclear cells, but to make the body, while in multi-organ confined to low expression in some of the anatomical location of the (mouse) more susceptible to intracellular pathogens. These mice machines in vivo MCP-1 serum levels, which shows in their circulating mononuclear cells may have been sensitized or MCP-1 stimulated the one kind Th2 dominant immune response [. The topical application of MCP-1 the best solution to anti-tumor pathological examination results confirmed not to cause significant damage to major organs of nude mice. It can give full play to its effect, reducing the required dose to avoid the above-mentioned side reactions. In summary, MCP-1 specific aggregation of mononuclear cells. So that aggregate migration to play a different anti-tumor mechanism, no significant side effects on normal cells. Sub-topical application, especially in patients assisted surgical treatment of osteosarcoma, an extremely important clinical significance.